- Home
- KMPR vs RARE Comparison
KMPR vs RARE Comparison
Compare KMPR & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMPR
- RARE
- Stock Information
- Founded
- KMPR 1990
- RARE 2010
- Country
- KMPR United States
- RARE United States
- Employees
- KMPR N/A
- RARE N/A
- Industry
- KMPR Property-Casualty Insurers
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- KMPR Finance
- RARE Health Care
- Exchange
- KMPR Nasdaq
- RARE Nasdaq
- Market Cap
- KMPR 4.5B
- RARE 5.2B
- IPO Year
- KMPR N/A
- RARE 2014
- Fundamental
- Price
- KMPR $66.34
- RARE $44.22
- Analyst Decision
- KMPR Strong Buy
- RARE Strong Buy
- Analyst Count
- KMPR 5
- RARE 14
- Target Price
- KMPR $75.20
- RARE $87.50
- AVG Volume (30 Days)
- KMPR 317.1K
- RARE 597.2K
- Earning Date
- KMPR 01-30-2025
- RARE 11-05-2024
- Dividend Yield
- KMPR 1.87%
- RARE N/A
- EPS Growth
- KMPR N/A
- RARE N/A
- EPS
- KMPR 4.20
- RARE N/A
- Revenue
- KMPR $4,639,300,000.00
- RARE $522,745,000.00
- Revenue This Year
- KMPR N/A
- RARE $27.36
- Revenue Next Year
- KMPR $12.15
- RARE $18.61
- P/E Ratio
- KMPR $15.82
- RARE N/A
- Revenue Growth
- KMPR N/A
- RARE 27.44
- 52 Week Low
- KMPR $47.12
- RARE $37.02
- 52 Week High
- KMPR $73.01
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- KMPR 39.53
- RARE 32.73
- Support Level
- KMPR $66.41
- RARE $48.29
- Resistance Level
- KMPR $68.21
- RARE $50.00
- Average True Range (ATR)
- KMPR 1.32
- RARE 1.55
- MACD
- KMPR -0.70
- RARE -0.16
- Stochastic Oscillator
- KMPR 9.57
- RARE 3.79
About KMPR Kemper Corporation
Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance. The company's property and casualty segment offers personal and commercial lines for home and automotive products. The company conducts its operations through two operating segments: Specialty Property & Casualty Insurance, and Life Insurance.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.